Metformin in Insulin Resistant Left Ventricular (LV) Dysfunction (TAYSIDE Trial)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Aaron K Wong, University of Dundee
ClinicalTrials.gov Identifier:
NCT00473876
First received: May 15, 2007
Last updated: May 28, 2013
Last verified: May 2013
  Purpose

Will metformin improve exercise capacity in chronic heart failure patients who has insulin resistance (pre-diabetic- means before they become diabetic)?


Condition Intervention Phase
Congestive Heart Failure
Insulin Resistance
Drug: Metformin
Drug: Matched Placebo (Capsules)
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Metformin in Insulin Resistant LV Dysfunction, a Double-blind, Placebo-controlled Trial (TAYSIDE Trial)

Resource links provided by NLM:


Further study details as provided by University of Dundee:

Primary Outcome Measures:
  • Peak VO2 [ Time Frame: 4 months ] [ Designated as safety issue: No ]
    Peak VO2 after 4 months of intervention with either metformin or placebo. The Mean difference between baseline and after 4 months was analyzed using t-test comparing metformin and placebo.


Secondary Outcome Measures:
  • Possible Mechanisms That Can Explain the Improvement of Exercise Capacity [ Time Frame: 4 months ] [ Designated as safety issue: No ]
    VE/VCO2 Slope, measurement of the abnormal ventilatory response to exercise identified by an increased slope of ventilation (L/min) vs. CO2 production (VE/VCO2) (L/min) to incremental workload


Enrollment: 62
Study Start Date: August 2007
Study Completion Date: April 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
Receiving Metformin for 4 months
Drug: Metformin
Started at 500mg bd for 2 weeks. If well tolerated, increase to 1000mg bd for 14 weeks
Placebo Comparator: 2
Matched Placebo for 4 months
Drug: Matched Placebo (Capsules)
Similar dosing regime as active comparator

Detailed Description:

Exercise incapacity is one of the major debilitating symptoms of heart failure patients. Studies showed that heart failure patients will become insulin resistance (IR) or vice versa, severity of heart failure also correlates with the severity of insulin resistance. A recent study demonstrated that if we correct diabetic patient insulin resistance by giving them a drug to make them more sensitive to the effects of insulin, their exercise capacity improves. Therefore, we think that the same effects might happen in heart failure patients who have been identified to the insulin resistance by blood test. Insulin resistance means that they have not yet become diabetic and it is a stage the diabetic patients go through before they develop diabetes.

Therefore, we plan to use a drug called metformin (a diabetic drug), give it to heart failure patients who also have IR for 4 months and examine the effects before and after 4 months of treatment. It is a double blind control study, therefore, neither the examiner nor the patient know which drug they receive (either active drug- Metformin, or a placebo).

The main objective is to assess their exercise capacity using an exercise test called Innocor System. It is a bicycle based exercise test that involves patient breathing into a mouth piece before and during exercise in order for the machine to work out the maximum oxygen consumption and pumping power of the heart.

The other objectives of the trial are looking at the possible mechanisms of improving exercise capacity. We aim to answer the following questions by doing the following tests:

Does exercise capacity improve because of

  1. The effect of metformin on the heart? We will answer this question by doing an ultrasound scan of the heart (Echocardiography)
  2. The effects on the blood vessels? We plan to perform a test called flow-mediated dilatation, it is an ultrasound scan of the artery in the arm and also assess the blood flow in the skin using a test called Laser Doppler scan (small amount of medication will be delivered through a small electric current and the blood vessels response will be assessed using the laser doppler scan)
  3. The effects on the muscle? We will do a muscle biopsy looking at the enzymes activities in the muscle before and after taking 4 months of medication.
  Eligibility

Ages Eligible for Study:   25 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients aged 25-80 yrs with compensated CHF in NYHA functional I-III with evidence of insulin resistance [fasting insulin resistance index values of > 2.7 are said to have insulin resistance].
  • Documented Left ventricular systolic dysfunction or LV ejection fraction < 35%

Exclusion Criteria:

  • Elderly patients (aged >80 yrs);
  • Patients with decompensated CHF (NYHA functional class IV and /or signs of decompensated CHF);
  • Renal dysfunction (serum creatinine > 160 mmol/L);
  • Patients who are unable to exercise including patients that will be excluded for reasons of safety or potential effects on exercise performance. Therefore, patients with angina or other cardiac or pulmonary symptoms potentially limiting exercise performance will be excluded.
  • Systolic blood pressure >190 mmHg at rest or >250 mmHg with exercise or diastolic blood pressure >95 mmHg at rest or >105 mmHg with exercise will also be a reason for exclusion;
  • Patients with underlying disease likely to limit life span and/or increase risk of interventions will be excluded i.e., cancer; cardiovascular disease .i.e., uncontrolled hypertension: SBP>180 mmHg or DBP, recent stroke, any severe chronic disease (including renal and hepatic disease).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00473876

Locations
United Kingdom
Medicine and Therapeutics, Ninewells Hospital
Dundee, Scotland, United Kingdom, DD1 9SY
Sponsors and Collaborators
University of Dundee
Investigators
Principal Investigator: Chim Lang, MD, FRCP University of Dundee, Scotland
  More Information

No publications provided by University of Dundee

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Aaron K Wong, Doctor, University of Dundee
ClinicalTrials.gov Identifier: NCT00473876     History of Changes
Other Study ID Numbers: WON001
Study First Received: May 15, 2007
Results First Received: January 14, 2013
Last Updated: May 28, 2013
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by University of Dundee:
Chronic Heart Failure
Insulin Resistance
Metformin
Peak VO2

Additional relevant MeSH terms:
Heart Failure
Insulin Resistance
Cardiovascular Diseases
Glucose Metabolism Disorders
Heart Diseases
Hyperinsulinism
Metabolic Diseases
Insulin
Metformin
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 21, 2014